Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

Rhea-AI Summary

Kronos Bio announces its participation in three upcoming healthcare conferences. CEO Norbert Bischofberger will represent Kronos Bio at these events. On May 28, 2024, he will join a virtual fireside chat at TD Cowen's Oncology Innovation Summit. On June 5, 2024, he will present a corporate overview and host investor meetings at the Jefferies Global Healthcare Conference in New York. Lastly, on June 11, 2024, he will participate in a fireside chat and host investor meetings at the Goldman Sachs Global Healthcare Conference in Miami. Live webcasts of these events will be available on Kronos Bio's website.

Kronos Bio is a clinical-stage company focused on developing small molecule therapeutics for cancers driven by deregulated transcription. Its drug candidates include KB-0742, targeting CDK9 for solid tumors, and KB-9558, targeting p300 for multiple myeloma.

Positive

• Kronos Bio's participation in three major healthcare conferences increases visibility and investor engagement.
• Live webcasts of the events can attract a broader audience and potentially new investors.
• CEO Norbert Bischofberger’s active involvement may signal strong leadership and confidence in the company’s direction.
• The company's focus on cancers driven by deregulated transcription addresses a critical and specific medical need.
• Kronos Bio's drug candidates, KB-0742 and KB-9558, are in advanced stages, indicating progress in the pipeline.

Negative

• The announcement lacks new clinical data or significant business developments, which might disappoint investors expecting substantial updates.
• Participation in conferences does not guarantee immediate financial or clinical advancement.
• No mention of financial performance or revenue projections, which may raise concerns among investors.

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that the company would participate in three upcoming healthcare conferences and events. Norbert Bischofberger, Ph.D., president and chief executive officer, will represent the company at these events.

• May 28th, 2024, Dr. Bischofberger will participate in a virtual fireside chat at 2:00 p.m. ET/11:00 a.m. PT at the TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA.
  
  
• June 5th, 2024, Dr. Bischofberger will present a corporate overview at 1:30 p.m. ET/10:30 a.m. PT during the Jefferies Global Healthcare Conference in New York, NY and host investor meetings the same day.
  
  
• June 11^th, 2024, Dr. Bischofberger will participate in a fireside chat at the Goldman Sachs 45^th Annual Global Healthcare Conference in Miami, FL at 10:40 a.m. ET/ 7:40 a.m. PT and host investor meetings the same day.
  
  

A live audio webcast of the events will be available on the Investors and Media section of the Kronos Bio website at https://ir.kronosbio.com/events-presentations. Replays of the webcasts will be available in the days following the events.

About Kronos Bio, Inc. 

Kronos Bio, Inc. is a clinical-stage company dedicated to developing small molecule therapeutics that address deregulated transcription, a hallmark of cancer and other diseases. Our proprietary discovery engine decodes complex transcription factor (TF) regulatory networks to identify druggable cofactors. We screen for and optimize small molecules that target these cofactors in a tumor-specific context. These efforts have yielded a preclinical pipeline along with two internally developed drug candidates. KB-0742 targets CDK9 to address MYC deregulation in solid tumors and KB-9558 targets p300 to address IRF4 dependence in multiple myeloma.  

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the Company on LinkedIn. 

Company Contact: 
Margaux Bennett 
Vice President, Corporate Development and Investor Relations, Kronos Bio 
650-781-5026 
mbennett@kronosbio.com 

FAQ

What are the dates for Kronos Bio's upcoming conference participations?

May 28, 2024, June 5, 2024, and June 11, 2024.

Who will represent Kronos Bio at the upcoming healthcare conferences?

CEO Norbert Bischofberger will represent the company.

Where can I watch the live webcasts of Kronos Bio's conference events?

Live webcasts will be available on the Investors and Media section of Kronos Bio's website.

What therapeutic areas are Kronos Bio’s drug candidates targeting?

Kronos Bio's drug candidates target cancers driven by deregulated transcription, such as MYC deregulation in solid tumors and IRF4 dependence in multiple myeloma.

What are the names of Kronos Bio's current drug candidates?

KB-0742 and KB-9558.

What is the focus of Kronos Bio’s proprietary discovery engine?

It decodes complex transcription factor regulatory networks to identify druggable cofactors.